beta-Adrenoceptor-blocking agents and the kidney: effect of nadolol and propranolol on the renal circulation

British Journal of Clinical Pharmacology
N K HollenbergJ M Sullivan


1 Nadolol was administered intravenously to five hypertensive patients and three healthy volunteers in balance on a 10 mEq sodium intake. 2 Nadolol (0.3-10.0 micrograms/kg) induced a significant, dose-related increase in renal blood flow, measured with radioxenon, with a maximum increase of 72 +/- 4 ml/100g/min (26%) at 3.0 micrograms/kg. 3 Heart rate and plasma renin activity decreased significantly over the same dose range. 4 The renal vascular response to nadolol contrasts sharply with those found with other beta-adrenoceptor-blocking agents. 5 The magnitude of the increase in renal blood flow, its time-course and the parallel fall in plasma renin activity raise the possibility that the renal vasodilation reflects the reversal of angiotensin's influence on the renal arterial bed.


Nov 1, 1992·Journal of Clinical Pharmacology·A V MehtaP J Rice
Jan 1, 1988·European Journal of Clinical Pharmacology·R A MorrisonD A Willard
Jan 1, 1987·European Journal of Clinical Pharmacology·A GattaA Ruol
Jan 1, 1986·European Journal of Clinical Pharmacology·Z Glück, F C Reubi
Jun 1, 1981·Irish Journal of Medical Science·A WatsonJ A Keogh
Oct 1, 1984·Irish Journal of Medical Science·E G BreenJ A Keogh
Mar 1, 1992·Journal of the American College of Cardiology·A V Mehta, B Chidambaram
Sep 17, 1981·The New England Journal of Medicine·W H Frishman
Sep 2, 1982·The New England Journal of Medicine·S C TextorR W Gifford
Jan 6, 1983·The New England Journal of Medicine
Oct 5, 1984·The American Journal of Medicine·N K Hollenberg
Jan 1, 1985·Clinical and Experimental Hypertension. Part A, Theory and Practice·M A van BaakJ F Smits
Oct 1, 1982·Archives internationales de physiologie et de biochimie·F Charocopos
Dec 6, 1985·The American Journal of Cardiology·N K Hollenberg
Feb 1, 1983·British Journal of Clinical Pharmacology·K BoehringerF C Reubi
Jan 1, 1988·Fundamental & Clinical Pharmacology·A BerdeauxJ F Giudicelli
Apr 1, 1982·Journal of Clinical Pharmacology·D T O'ConnorK L Duchin
Dec 15, 1986·The American Journal of Medicine·N K Hollenberg
Jan 23, 1987·The American Journal of Cardiology·N K Hollenberg
Jan 1, 1988·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·G IdéoD Grimoldi
Nov 26, 1986·The American Journal of Cardiology·M SolimonV M Campese
Aug 1, 1987·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·J H BauerA Lau
Sep 1, 1985·British Journal of Clinical Pharmacology·I G MackayM L Watson
Jan 15, 1981·Klinische Wochenschrift·F W Lohmann
Oct 1, 1983·British Journal of Clinical Pharmacology·W G O'CallaghanK O'Malley
Jul 1, 1980·British Journal of Clinical Pharmacology·R WilkinsonJ D Harry
Aug 10, 2000·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·V PiriouJ J Lehot


Oct 1, 1977·Kidney International·N K HollenbergD F Adams
Dec 15, 1976·Experientia·C BianchiP Papalexiou
Jun 22, 1974·British Medical Journal·A Snell, M Wallace
Jun 8, 1974·British Medical Journal·F D Thompson, A M Joekes
Sep 1, 1966·The American Journal of Cardiology·S A Stephen
Mar 1, 1973·Kidney International·N K HollenbergJ P Merrill

Related Concepts

Angiotensin A
Entire Renal Artery
Structure of Posterior Renal Segment
Renal Blood Flow
Renin Activity

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Synapse Loss as Therapeutic Target in MS

As we age, the number of synapses present in the human brain starts to decline, but in neurodegenerative diseases this occurs at an accelerated rate. In MS, it has been shown that there is a reduction in synaptic density, which presents a potential target for treatment. Here is the latest research on synapse loss as a therapeutic target in MS.

Artificial Intelligence in Cardiac Imaging

Artificial intelligence (ai) techniques are increasingly applied to cardiovascular (cv) medicine in cardiac imaging analysis. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

Social Learning

Social learning involves learning new behaviors through observation, imitation and modeling. Follow this feed to stay up to date on the latest research.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Single Cell Chromatin Profiling

Techniques like ATAC-seq and CUT&Tag have the potential to allow single cell profiling of chromatin accessibility, histones, and TFs. This will provide novel insight into cellular heterogeneity and cell states. Discover the latest research on single cell chromatin profiling here.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells.